Home
Welcome Note
Committees
Faculty
Timetable
Scientific Program
Poster Presentations
Poster Presentation Guidelines
Sponsorship & Exhibition
Sponsors & Exhibitors
Sponsorship Prospectus
Exhibition Floorplan
Exhibitor's Manual
Registration
Accommodation
CME
Tours
Accompanying Persons Tours
General Information
Before you travel ...
Webcasting
Wednesday, July 4, 2012
Thursday, July 5, 2012
About Tel-Aviv
About Israel
From Dan to Eilat
The People
Israeli Advanced Medicine
Partners
Contact Us
Friends of Israel
Urological Symposium

Tel Aviv Hilton, Tel-Aviv, Israel, July 3-5, 2012
  Webcasting - Wednesday, July 2, 2014 Print

For Thursday's Webcasting Click here

Screening and prevention
PSA will no longer be used for screening
Yes: E. Klein, USA
Screening and prevention
PSA will no longer be used for screening
No: S. Loeb, USA
Prostate cancer prevention will be dead
Yes: M. Litwin, USA
Prostate cancer prevention will be dead
No: N. Fleshner, Canada
5-Alpha reductase inhibitors will disappear due to concern about high-grade prostate cancer
R. Reiter, USA
The modified Gleason’s grading system will be re-modified and Gleason’s pattern 3 will no longer be considered “cancer”
J. Srigley, Canada
Active surveillance will be promoted to patients with Gleason’s 7 (3+4)
Yes: L. Klotz, Canada
Active surveillance will be promoted to patients with Gleason’s 7 (3+4)
No: M. Soloway, USA
Radical prostatectomy
Open radical prostatectomy will continue to be a common operation
M. Zerbib, France
Robotic radical prostatectomy will replace laparoscopic and open radical prostatectomy
C. Abbou, France
Focal and ablative treatment
Focal treatment will be widely accepted and utilized
A. Villers, France
Cryotherapy will be used for salvage only
A. Belldegrun, USA
HIFU will remain a “niche” treatment
Yes: J. Nelson, USA
HIFU will remain a “niche” treatment
No: I. Grunberger, USA
Is there a best anti-muscarinic drug?
J. Golomb, Israel
Managing the anti-muscarinic non-responders
Sacral neuro-stimulation
Pathogenic mechanisms linking BPH/LUTS and ED
S. Glina, Brazil
Impact of therapies for LUTS on ED
Medications
A. Greenstein, Israel
Impact of therapies for LUTS on ED
Surgery
E.F. Becher, Argentina
Impact of therapies for ED on LUTS
J. Chen, Israel
The rational for treating LUTS/BPH with PDE5-Is
Studies on the use of PDE5-Is for LUTS
Y. Vardi, Israel
Evolution of continent urinary diversion: Practical tips in construction and management
A. Sagalowsky, USA
Update on neoadjuvant treatment
A. Sella, Israel
The therapy of metastatic RCC
G. Bratslavsky, USA
Case Discussion




info@comtecmed.com
www.comtecmed.com
Headquarters & Administration:
53 Rothschild Boulevard,
PO Box 68,
Tel Aviv, 6100001, Israel
Tel: +972-3-5666166
Fax: +972-3-5666177 Email: Info@comtecmed.com
Comtec Spain:
Bailen, 95 - 97,
pral.1.a - 08009
Barcelona, Spain
Tel: +34-932081145
Fax: +34-934579291
Email: spain@comtecmed.com
Comtec China:
Suite 405, Universal Center Building
175 Xiang Yang Road South,
Shanghai 200031, China
Tel: +86-21-54660460
Fax: +86-21-54660450
Email: china@comtecmed.com
 
 
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 07/28/2014 Created by     WebStudio.co.il